INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
April 11 2023 - 8:00AM
INmune Bio, Inc. (NASDAQ: INMB) (the
“Company”), a clinical-stage immunology company focused on
developing treatments that harness the patient’s innate immune
system to fight disease, is presenting data on the use of INB03, a
dominant-negative TNF inhibitor of soluble TNF (sTNF) in the
treatment of high-risk MUC4 expressing HER2+ and triple negative
breast cancer. Roxana Schillaci Ph.D. of Instituto de
Biología y Medicina Experimental in Buenos Aries, Argentina, will
present data at the American Association of Cancer Research Annual
Meeting 2023 in Orlando Florida and has published a paper in
Cancers as part of the Special Issue: Targeted Therapeutic Options
and Future Perspectives for HER2-Positive Breast Cancer.
MUC4, an easily measured glycoprotein on the
cell surface of approximately one third of women with HER2+ or
TNBC, predicts poor survival and treatment resistant disease with
increased metastatic potential. Several resistance mechanisms
are active in MUC4-expressing tumors including resistance to
trastuzumab-based antibody drug conjugates such as
trastuzumab-deruxtecan (Enhertu™). Neutralizing soluble TNF
with INB03, a dominant negative inhibitor of sTNF, decreases MUC4
expression, improves function of trastuzumab based immunotherapies,
increases anti-tumor macrophage function, increases tumor
infiltrating lymphocyte populations, and decreases the metastatic
potential of these high-risk tumors. These changes should
improve the response to immunotherapy.
"We understand how MUC4 causes resistance to
HER2-targeted therapies and have developed a strategy to overcome
this resistance,” said Roxana Schillaci Ph.D., lead scientist on
the program from the Instituto de Biología y Medicina Experimental
in Buenos Aires, Argentina. “We believe reversing expression
in MUC4 in TNBC may provide therapeutic benefits. Reversing drug
therapy resistance mechanisms by targeting soluble TNF alpha with
INB03 may be a more efficient and safer way to improve response to
therapy in women with relapsing breast cancer."
“Despite recent innovations in the treatment of
HER2+ and triple-negative breast cancer, an unacceptably high
number of women have resistant disease,” said RJ Tesi M.D., CEO of
INmune Bio. “MUC4 expression can be determined before treatment is
initiated. Modifying the treatment to account for this new
resistance mechanism may make is difference in the care of these
woman."
Session title: Immune Response to Therapy
Poster Title: Soluble TNFα blockade
enhances trastuzumab deruxtecan antitumor effect in HER2-positive
breast cancer
Session Date/Time: Monday April 17, 2023 / 9.00 am
to 12.30pm Poster Board Number/Abstract Presentation
Number: 20 / 2273 Location/Poster Board Number:
Section 43 / 20
Session title: Metastasis Promoting and Suppressing
Genes
Poster Title: New Therapeutic approach for triple
negative breast cancer: TNF blockade and MUC4 expression as a
prognostic biomarker
Session Date/Time: Monday April 17, 2023 / 9.00 am
to 12.30pm Poster Board Number/Abstract Presentation
Number: 29/1306 Location/Poster Board Number:
Section 4/29
A PDF version of the article in the special edition of Cancers
is available here.
About INB03
INB03 is a DN-TNF inhibitor that neutralizes
soluble TNF (sTNF) without affecting trans membrane TNF (tmTNF) or
TNF receptors. Compared to currently available non-selective
TNF inhibitors, INB03 preserves the immune response to cancer by
decreasing immunosuppressive cells in the TME including TAM and
MDSC while promoting recruitment of anti-tumor immune cells
including cytolytic CD8+ lymphocytes, NK cells and anti-tumor
macrophages. INB03 has completed an open label
dose-escalation Phase I trial in patients with advanced
cancer. In that trial, INB03 was found to be safe and well
tolerated - no dose limiting toxicity was found. INB03
decreased blood biomarkers of inflammation in patients with
advanced cancer. INMB is planning a Phase II trial that uses
IN03 as part of combination therapy.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly
traded (NASDAQ: INMB), clinical-stage biotechnology company focused
on developing treatments that target the innate immune system to
fight disease. INmune Bio has two product platforms that are both
in clinical trials: The Dominant-Negative Tumor Necrosis Factor
(DN-TNF) product platform utilizes dominant-negative technology to
selectively neutralize soluble TNF, a key driver of innate immune
dysfunction and a mechanistic driver of many diseases. DN-TNF
product candidates are in clinical trials to determine if they can
treat cancer (INB03™), Early Alzheimer’s disease and
treatment-resistant depression (XPro™). The Natural Killer Cell
Priming Platform includes INKmune™ developed to prime a patient’s
NK cells to eliminate minimal residual disease in patients with
cancer. INmune Bio’s product platforms utilize a precision medicine
approach for the treatment of a wide variety of hematologic and
solid tumor malignancies, and chronic inflammation. To learn more,
please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is
no assurance that any specific outcome will be achieved. Any
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595, and INKmune™
are still in clinical trials or preparing to start clinical trials
and have not been approved by the US Food and Drug Administration
(FDA) or any regulatory body and there cannot be any assurance that
they will be approved by the FDA or any regulatory body or that any
specific results will be achieved. The factors that could cause
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720 info@inmunenbio.com
Investor Contact: Jason Nelson, Core IR(516) 842-9614 x-823
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2023 to Apr 2024